Product & Service News

LONDON--(BUSINESS WIRE)--Hanshow, a global leader in electronic shelf labels (ESL) and digital store solutions, has entered into a multi-year research collaboration with the University of Cambridge, one of the world’s most prestigious academic institutions. The partnership will focus on joint research and innovation in next-generation intelligent hybrid wireless technologies, marking an important milestone in Hanshow’s continued investment in core technologies and long-term innovation. This col...

TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (TOKYO: 4883) today announced that its research article titled “Efficient LAMA1 gene activation by epigenome editing as a therapeutic approach for LAMA2-CMD” has been published in the peer-reviewed journal Human Gene Therapy. The publication highlights compelling preclinical evidence that Modalis’ proprietary CRISPR-GNDM® epigenome editing technology can safely and robustly activate the LAMA1 gene as a novel therapeutic s...

TAIPEI, Taiwan--(BUSINESS WIRE)--Phison Electronics (8299TT), a leading provider of NAND controllers and NAND storage solutions, today (December 24, 2025) announced its participation in the inaugural International FHIR Server Performance Competition hosted by Taiwan’s Ministry of Health and Welfare (MOHW). Leveraging its self-developed, on-premises high-performance storage server solution, Phison received two major awards — the Best Real-Time Application Award and the Best Hardware Performance...

SHENZHEN, China--(BUSINESS WIRE)--To celebrate its 10th anniversary, Geekvape reached the summit of Mount Everest after months of preparation, training, and a two-week ascent. More than a symbolic act, it was a real test of endurance, discipline, and belief—the same values that have defined Geekvape for a decade. Inspired by Everest: Respecting Everest, Respecting the Challenge For Geekvape, the journey began months in advance with route planning, environmental assessment, physical training, an...

SINGAPORE--(BUSINESS WIRE)--Z.ai released GLM-4.7 ahead of Christmas, marking the latest iteration of its GLM large language model family. As open-source models move beyond chat-based applications and into production environments, they are increasingly expected to handle long-running tasks. GLM-4.7 has been developed with these requirements in mind. Unlike earlier systems focused on single-turn interactions, GLM-4.7 targets development environments that involve longer task cycles, frequent tool...

DALLAS--(BUSINESS WIRE)--Generational Group, a leading mergers and acquisitions advisory firm for privately held businesses, is pleased to announce the sale of Swift Health Medical Group to a Private Medical Practice. The acquisition closed November 25, 2025. Headquartered in Atlanta, Georgia, Swift Health Medical Group is an urgent care clinic that provides immediate, non-emergency medical services for patients of all ages. The clinic offers walk-in treatment for common illnesses and injuries,...

UPPER NYACK, N.Y.--(BUSINESS WIRE)--GHLF English and Spanish Language Lupus Help Centers Reach New Patients...

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement. YARTEMLEA is the first and only approved lectin pathway inhibitor. YARTEMLEA selectively inhibits MASP-2, the ef...

NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (OTCQB: QTIH) (“QT Imaging” or the “Company”), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today confirms that it finalized the shipment of 40 scanners and met its revenue guidance of more than $18 million in 2025. “2025 was a transitional year for QT Imaging as we moved from early commercialization to scaled execution. We met our objectives and shipped scanners in...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare’s polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the “Gilead Agreement”). “We are pleased to announce this transaction which combines Gilead’s leading expertise in oncology research and development with RP-3467, a potential best-in-class...